Upregulation of GSK3beta expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci).

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Brain Research

• Publication date

  2008-02-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.brainres.2007.12.031PMID 18221734
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS.

  2007cited by this paper
• Glycogen synthase kinase 3β and Alzheimer’s disease: pathophysiological and therapeutic significance

  2006cited by this paper
• Tau protein hyperphosphorylation in sporadic ALS with cognitive impairment

  2006cited by this paper
• GSK-3 is essential in the pathogenesis of Alzheimer's disease

  2006cited by this paper
• The role of CDK5/P25 formation/inhibition in neurodegeneration.

  2006cited by this paper
• Amyotrophic lateral sclerosis with dementia: an autopsy case showing many Bunina bodies, tau-positive neuronal and astrocytic plaque-like pathologies, and pallido-nigral degeneration

  2006cited by this paper
• The Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation*

  2006cited by this paper
• Tau protein aggregation in the frontal and entorhinal cortices as a function of aging.

  2005cited by this paper
• Is there a role of the cyclin-dependent kinase 5 activator p25 in Alzheimer's disease?

  2005cited by this paper
• A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons

  2005cited by this paper
• Phosphorylated tau and the neurodegenerative foldopathies.

  2005cited by this paper
• Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.

  2005cited by this paper
• Role of GSK‐3β activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene

  2005cited by this paper
• Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick’s disease

  2004cited by this paper
• Cyclin‐dependent kinase‐5 in neurodegeneration

  2004cited by this paper
• Cdk5: mediator of neuronal death and survival.

  2004cited by this paper
• Cyclin‐dependent kinase‐5 in neurodegeneration

  2004cited by this paper
• A novel CDK5‐dependent pathway for regulating GSK3 activity and kinesin‐driven motility in neurons

  2004cited by this paper
• Mutant superoxide dismutase 1 causes motor neuron degeneration independent of cyclin‐dependent kinase 5 activation by p35 or p25

  2004cited by this paper
• Microtubule-associated tau protein positive neuronal and glial inclusions in ALS

  2003cited by this paper
• The Regulation of Cyclin-Dependent Kinase 5 Activity through the Metabolism of p35 or p39 Cdk5 Activator

  2003cited by this paper
• Cyclin-dependent kinases in neural development and degeneration

  2003cited by this paper
• Cyclin-dependent kinase 5 (CDK5) and neuronal cell death

  2003cited by this paper
• Biochemical and Ultrastructural Study of Neurofibrillary Tangles in Amyotrophic Lateral Sclerosis/Parkinsonism‐Dementia Complex in the Kii Peninsula of Japan

  2003cited by this paper
• Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β

  2002cited by this paper
• The active form of glycogen synthase kinase-3β is associated with granulovacuolar degeneration in neurons in Alzheimer's disease

  2002cited by this paper
• Cdk5 sinks into ALS.

  2002cited by this paper
• Cognitive impairment in sporadic ALS

  2001cited by this paper
• The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.

  2001cited by this paper
• GSK3 takes centre stage more than 20 years after its discovery.

  2001cited by this paper
• Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions.

  2001cited by this paper
• Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice.

  2000cited by this paper
• El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis

  2000cited by this paper
• Cyclin-dependent kinase-5 (CDK5) and amyotrophic lateral sclerosis

  2000cited by this paper
• Glycogen Synthase Kinase-3β Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Human Four-repeat Tau Transgenic Mice*

  2000cited by this paper
• Developmental expression and localization of glycogen synthase kinase-3beta in rat brain.

  1999cited by this paper
• Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration

  1999cited by this paper
• GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis.

  1998cited by this paper
• Distribution, Levels, and Activity of Glycogen Synthase Kinase‐3 in the Alzheimer Disease Brain

  1997cited by this paper
• Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly

  1996cited by this paper
• Wingless inactivates glycogen synthase kinase‐3 via an intracellular signalling pathway which involves a protein kinase C.

  1996cited by this paper
• Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly.

  1996cited by this paper
• Modulation of the glycogen synthase kinase‐3 family by tyrosine phosphorylation.

  1993cited by this paper
• Rare neuropil threads in amyotrophic lateral sclerosis and parkinsonism-dementia on Guam and in the Kii Peninsula of Japan.

  1993cited by this paper
• Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase.

  1992cited by this paper
• Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments.

  1992cited by this paper
• Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments.

  1992cited by this paper
• Glycogen synthase kinase‐3 and the Alzheimer‐like state of microtubule‐associated protein tau

  1992cited by this paper

• Inhibiting Glycogen Synthase Kinase 3 Suppresses TDP-43-Mediated Neurotoxicity in a Caspase-Dependent Manner

  2026cites this paper
• ATH-1105 mitigates multiple pathologies in ALS models both alone and in combination with riluzole

  2026cites this paper
• Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis

  2025cites this paper
• Lithium mitigates hippocampal tau pathology in a rodent model of traumatic brain injury

  2025cites this paper
• TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?

  2025cites this paper
• Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery

  2025cites this paper
• Unlocking the therapeutic potential of protein kinase inhibitors in neurodegenerative and psychiatric disorders

  2025cites this paper
• Polyphenols as Wnt/β‐catenin pathway modulators: A promising strategy in clinical neurodegeneration

  2025cites this paper
• Inhibiting glycogen synthase kinase 3 suppresses TDP-43-mediated neurotoxicity in a caspase-dependent manner

  2025cites this paper
• Alterations to metabolic hormones in amyotrophic lateral sclerosis and frontotemporal dementia postmortem human tissue

  2024cites this paper
• TDP-43 proteinopathy in ALS is triggered by loss of ASRGL1 and associated with HML-2 expression

  2024cites this paper
• Unknown roles of tau pathology in neurological disorders. Challenges and new perspectives.

  2024cites this paper
• Discovery of Novel Biomarkers with Extended Non-Coding RNA Interactor Networks from Genetic and Protein Biomarkers

  2024cites this paper
• Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue

  2024cites this paper
• The paradigm of amyloid precursor protein in amyotrophic lateral sclerosis: The potential role of the 682YENPTY687 motif

  2023cites this paper
• New insights into glycogen synthase kinase-3: A common target for neurodegenerative diseases.

  2023cites this paper
• The role of glycogen synthase kinase 3 beta in neurodegenerative diseases

  2023cites this paper
• WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective

  2023cites this paper
• Amyotrophic lateral sclerosis with TDP‐43 abnormalities exhibiting globular glial tau inclusions in frontotemporal lobes and pallido‐nigral system

  2022cites this paper
• Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward

  2022cites this paper
• Decoding Amyotrophic Lateral Sclerosis: A Systems Biology Approach

  2022cites this paper
• Inhibiting glycogen synthase kinase 3 suppresses TDP-43-mediated neurotoxicity in a caspase-dependant manner

  2021cites this paper
• Regulation of Endoplasmic Reticulum–Mitochondria Tethering and Ca2+ Fluxes by TDP-43 via GSK3β

  2021cites this paper
• Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis

  2021cites this paper
• Targeting Axonal Transport: A New Therapeutic Avenue for ALS

  2020cites this paper
• Modulated Expression of the Protein Kinase GSK3 in Motor and Dopaminergic Neurons Increases Female Lifespan in Drosophila melanogaster

  2020cites this paper
• Tau phosphorylation by glycogen synthase kinase 3β modulates enzyme acetylcholinesterase expression

  2020cites this paper
• Recent Advances on the Role of GSK3β in the Pathogenesis of Amyotrophic Lateral Sclerosis

  2020cites this paper
• Protein kinase inhibitors for amyotrophic lateral sclerosis therapy

  2020cites this paper
• SCF‐Slimb is critical for Glycogen synthase kinase‐3β‐mediated suppression of TAF15‐induced neurotoxicity in Drosophila

  2020cites this paper
• Alterations in Tau Metabolism in ALS and ALS-FTSD

  2020cites this paper
• Tauopathy

  2019cites this paper
• Pathogenic Tau Protein Species: Promising Therapeutic Targets for Ocular Neurodegenerative Diseases

  2019cites this paper
• β-catenin aggregation in models of ALS motor neurons: GSK3β inhibition effect and neuronal differentiation.

  2019cites this paper
• FUS(1-359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy

  2018cites this paper
• Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging

  2018influential citation
• Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis—Frontotemporal Spectrum Disorder (ALS-FTSD). A Review

  2018cites this paper
• Pathways of p38, GSK3b, and Their Extensions to Mental Health

  2017cites this paper
• Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases.

  2017cites this paper
• Threonine175, a novel pathological phosphorylation site on tau protein linked to multiple tauopathies

  2017cites this paper
• Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research?

  2017cites this paper
• The Behavioural Phenotype of pThr175-Tau Expression in the Hippocampus of Female Adult Sprague Dawley Rats

  2016cites this paper
• Efecto de la inhibición dual de GSK-3 y PDE-7 en un modelo murino de esclerosis lateral amiotrófica

  2016cites this paper
• Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy

  2016cites this paper
• Protective effects of isolecanoric acid on neurodegenerative in vitro models.

  2016cites this paper
• Intravenous injection of l-BMAA induces a rat model with comprehensive characteristics of amyotrophic lateral sclerosis/Parkinson-dementia complex.

  2016cites this paper
• Thr175-phosphorylated tau induces pathologic fibril formation via GSK3β-mediated phosphorylation of Thr231 in vitro.

  2015cites this paper
• Analysis of β-N-methylamino-L-alanine (L-BMAA) neurotoxicity in rat cerebellum.

  2015cites this paper
• Synthèse et évaluation biologique de nouveaux composés hétérocycliques potentiellement inhibiteurs de protéine-kinases

  2015cites this paper
• Glycogen synthase kinase-3β expression and phosphorylation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis.

  2014cites this paper
• Mechanisms of action of brain insulin against neurodegenerative diseases

  2014cites this paper
• Therapeutic Potential of Mood Stabilizers Lithium and Valproic Acid: Beyond Bipolar Disorder

  2013cites this paper
• Mechanisms underlying beta-N-methylamino-L-alanine neurotoxicity in different model systems

  2013cites this paper
• Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.

  2013cites this paper
• β-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS.

  2013cites this paper
• β-N-methylamino-L-alanine induces changes in both GSK3 and TDP-43 in human neuroblastoma.

  2013cites this paper
• Endogenous GSK‐3/Shaggy Regulates Bidirectional Axonal Transport of the Amyloid Precursor Protein

  2013cites this paper
• A high throughput and sensitive method correlates neuronal disorder genotypes to Drosophila larvae crawling phenotypes

  2012cites this paper
• Widespread neuronal and glial hyperphosphorylated tau deposition in ALS with cognitive impairment

  2012cites this paper
• Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study

  2012cites this paper
• Measuring molecular motor forces to probe transport regulation in vivo

  2012cites this paper
• Mechanisms of lithium ’ s neuroprotective actions 2 . 1 Lithium as a multi-functional neuroprotectant

  2011cites this paper
• Oxidative Stress and Alzheimer Disease: Mechanisms and Therapeutic Opportunities

  2011cites this paper
• The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy.

  2011cites this paper
• Ghrelin protects spinal cord motoneurons against chronic glutamate-induced excitotoxicity via ERK1/2 and phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3β pathways.

  2011cites this paper
• FTD and ALS: a tale of two diseases.

  2011cites this paper
• Brief Review of the Role of Glycogen Synthase Kinase-3β in Amyotrophic Lateral Sclerosis

  2011cites this paper
• The Frontotemporal Syndromes of ALS. Clinicopathological Correlates

  2011cites this paper
• Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

  2010cites this paper
• GSK-3b : une kinase au cœur des maladies neuro-?

  2010cites this paper
• GSK-3β : une kinase au cœur des maladies neuro-dégénératives ?

  2010cites this paper
• [GSK-3beta: a central kinase for neurodegenerative diseases?].

  2010cites this paper
• Integrative gene-tissue microarray-based approach for identification of human disease biomarkers: application to amyotrophic lateral sclerosis.

  2010cites this paper
• Tau phosphorylation at threonine‐175 leads to fibril formation and enhanced cell death: implications for amyotrophic lateral sclerosis with cognitive impairment

  2009cites this paper
• Lithium and Neuropsychiatric Therapeutics: Neuroplasticity via Glycogen Synthase Kinase-3β, β-Catenin, and Neurotrophin Cascades

  2009cites this paper
• Nanotechnology, Nanostructure, and Nervous System Disorders

  2009cites this paper
• Immunohistochemical expression of IGF‐I and GSK in the spinal cord of Kii and Guamanian ALS patients

  2009cites this paper
• Chapter 1 Recent Advances in the Discovery of GSK-3 Inhibitors and a Perspective on their Utility for the Treatment of Alzheimer's Disease

  2009cites this paper
• The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis

  2008cites this paper